PubMed Health⌕ Search

Biomedical subjects

C Giansante

Publications and source records attributed to C Giansante.

26 records · Page 2Linked to original sources
PubMed1982

[Platelet aggregation in hyperlipoproteinemias].

The Authors studied platelet aggregation in 42 hyperlipoproteinemic patients (10 with type IIA familiar, 7 with type IIA, 7 with type IIB, 18 with type IV and V). None of them suffered from clinically detectable vascular complications. The control group included 42 normolipoproteinemic subjects, closely matched for age and sex. Platelet aggregation, according Born's method, was statistically increased in hyperlipoproteinemia type IIA, but only when induced by epinephrine as aggregating agent. No statistical significance was demonstrated when hyperlipoproteinemic smokers and no smokers were compared. A positive family history of myocardial infarction and/or diabetes mellitus could be demonstrate affect on platelet aggregation.

Adolescent↗
PubMed1981

[Platelet factor 3 and 4 in juvenile diabetes and in children of diabetic mothers].

We studied 91 children, distributed, as follows, in four groups: Group A, including 24 children (average age 11.4 +/- 0.7) with juvenile onset diabetes (duration less than 4 years), without any clinically apparent vascular disorder. Group B: 22 matched controls (average age 11.5 +/- 0.53). Group C: 25 newborns (average age 3.7 +/- 0.3) of diabetic mothers (B Group in P. White classification). Group D: 20 matched controls (average age 2.8 +/- 0.3). All were tested for total, HDL, LDL-cholesterol, triglycerides, fasting blood sugar, systolic and diastolic blood pressure. In all the subjects we performed: -- PF4 (by H.T.C.H., according O'Brien et al., 1975) on PPP and on PRP (300,000-350,000 platelets/microliters) after platelet aggregation with 4.0 10(-6)M epinephrine (Born's method). -- PF3 (b a Stypven time) on frozen-thawed (three times) PRP and on PRP after p.a. with 4.0 10(-6)M epinephrine. No statistically significant difference was noted in PF3 values between A-C groups and their respective control groups (B-D). PF4 was more represented on diabetic's PPP (group A), whilst no difference was noted after aggregation. This increase suggests in early juvenile onset diabetes, without any clinically apparent disease, an "in vivo" platelet activation, which may be important in thromboembolic disorders of diabetics.

Blood Coagulation Factors↗
PubMed1975

[Behaviour of blood digoxin, determined by the radioimmunity method, in patients with renal failure (author's transl)].

The authors used radioimmunity to study blood digoxin behaviour in patients with normal renal function and with variable BUN. The computerized and mathematically considered data showed that digitalic intoxication occurs with higher digoxin blood levels in patients with renal failure than in normal renal function cases. In the first case, moreover, it occurs sooner than in the second one, and the total digoxin dose is smaller than in normal patients. We have found that the large range of digosin blood levels is vital in deciding the therapeutic and toxic dose; that may be done, for most cases, following the estimate of the theoretical saturation dose using our method.

Aged↗
PubMedDate not supplied

Treatment of intermittent claudication with antiplatelet agents.

In a double-blind study, 296 patients with intermittent claudication (Fontaine stage II) were treated with 250 mg ticlopidine twice daily, 500 mg aspirin every third day plus 75 mg dipyridamole three times daily, or 300 mg xanthinol nicotinate three times daily for 6 months. Ticlopidine and aspirin/dipyridamole, but not xanthinol nicotinate, improved platelet aggregation, reduced beta-thromboglobulin, platelet factor IV and fibrinopeptide A concentrations, and increased antithrombin III concentrations and red blood cell filterability. No changes in lipid profiles, platelet count or fibrinogen were recorded following any treatment. The doppler systolic blood pressure ratio was improved in patients treated with ticlopidine or aspirin/dipyridamole, but not with xanthinol nicotinate. It is concluded that antiplatelet treatment is useful for the treatment of limb arteriopathy.

Adult↗